# Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

> clinical trial · VERIFIED · 2026-07-16

Status: ACTIVE_NOT_RECRUITING · Sponsor: Octapharma · Condition: Primary Immune Deficiency

- Company: Octapharma
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT04640142

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.